ES2849187T3 - Método para activar células T auxiliares - Google Patents
Método para activar células T auxiliares Download PDFInfo
- Publication number
- ES2849187T3 ES2849187T3 ES11830662T ES11830662T ES2849187T3 ES 2849187 T3 ES2849187 T3 ES 2849187T3 ES 11830662 T ES11830662 T ES 11830662T ES 11830662 T ES11830662 T ES 11830662T ES 2849187 T3 ES2849187 T3 ES 2849187T3
- Authority
- ES
- Spain
- Prior art keywords
- hla
- molecule
- drb1
- peptide
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4242—Transcription factors, e.g. SOX or c-MYC
- A61K40/4243—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010225806 | 2010-10-05 | ||
| PCT/JP2011/072874 WO2012046730A1 (ja) | 2010-10-05 | 2011-10-04 | ヘルパーｔ細胞の活性化方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2849187T3 true ES2849187T3 (es) | 2021-08-16 |
Family
ID=45927725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11830662T Active ES2849187T3 (es) | 2010-10-05 | 2011-10-04 | Método para activar células T auxiliares |
Country Status (21)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130062368A (ko) | 2003-11-05 | 2013-06-12 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | Ｗｔ１ 유래의 ｈｌａ-ｄｒ 결합성 항원 펩티드 |
| US8765687B2 (en) | 2005-10-17 | 2014-07-01 | Sloan Kettering Institute For Cancer Research | WT1 HLA class II-binding peptides and compositions and methods comprising same |
| EP3117836A1 (en) | 2006-04-10 | 2017-01-18 | Sloan Kettering Institute For Cancer Research | Immunogenic wt-1 peptides and uses thereof |
| UA101608C2 (uk) | 2007-02-27 | 2013-04-25 | Интэрнэшнл Инститьют Оф Кэнсэр Иммунолоджы, Инк. | Спосіб активації хелперних t-клітин |
| AR076349A1 (es) | 2009-04-23 | 2011-06-01 | Int Inst Cancer Immunology Inc | Peptido auxiliar del antigeno del cancer |
| ES2849187T3 (es) * | 2010-10-05 | 2021-08-16 | Int Inst Cancer Immunology Inc | Método para activar células T auxiliares |
| EP3520810A3 (en) | 2012-01-13 | 2019-11-06 | Memorial Sloan-Kettering Cancer Center | Immunogenic wt1 peptides and use thereof |
| CN104797711B (zh) * | 2012-09-12 | 2018-09-21 | 株式会社癌免疫研究所 | 抗原特异性辅助性t细胞受体基因 |
| SG11201504530VA (en) * | 2012-12-17 | 2015-07-30 | Otsuka Pharma Co Ltd | Method for activating helper t cell |
| ES2832546T3 (es) | 2013-01-15 | 2021-06-10 | Memorial Sloan Kettering Cancer Center | Péptidos WT-1 inmunogénicos y métodos de uso de los mismos |
| US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
| RU2668560C2 (ru) | 2013-03-29 | 2018-10-02 | Сумитомо Дайниппон Фарма Ко., Лтд. | Конъюгированная вакцина на основе пептида антигена wt1 |
| JP6005305B2 (ja) * | 2014-02-26 | 2016-10-12 | テラ株式会社 | Ｗｔ１抗原性ポリペプチド、及び該ポリペプチドを含む抗腫瘍剤 |
| KR102588853B1 (ko) | 2014-12-25 | 2023-10-16 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | T 세포 집단의 개변 방법 |
| CN106565836B (zh) * | 2015-10-10 | 2020-08-18 | 中国科学院广州生物医药与健康研究院 | 高亲和力的可溶性pdl-1分子 |
| DK3539974T5 (en) | 2016-11-09 | 2024-05-27 | Univ Osaka | Method for modifying t cell population |
| EP3549957A4 (en) * | 2016-11-30 | 2020-08-05 | Sumitomo Dainippon Pharma Co., Ltd. | AUXILIARY PEPTIDE WT1, AND COMBINATION OF DUDIT PEPTIDE AND CONJUGATE PEPTIDE ANTIGENIC FOR CANCER |
| WO2019131722A1 (ja) * | 2017-12-27 | 2019-07-04 | 大日本住友製薬株式会社 | Ｗｔ１由来ペプチドのコンジュゲート体およびこれを含む組成物 |
| EP4036235A1 (en) * | 2018-02-15 | 2022-08-03 | National University Corporation Asahikawa Medical University | Cancer antigen peptide |
| KR20210049119A (ko) * | 2018-08-22 | 2021-05-04 | 프레드 헛친슨 켄서 리서치 센터 | Kras 또는 her2 항원을 표적으로 하는 면역요법 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5726288A (en) | 1989-11-13 | 1998-03-10 | Massachusetts Institute Of Technology | Localization and characterization of the Wilms' tumor gene |
| ATE420112T1 (de) | 1998-07-31 | 2009-01-15 | Int Inst Cancer Immunology Inc | Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1 |
| US7063854B1 (en) | 1998-09-30 | 2006-06-20 | Corixa Corporation | Composition and methods for WTI specific immunotherapy |
| US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| WO2000018795A2 (en) | 1998-09-30 | 2000-04-06 | Corixa Corporation | Compositions and methods for wt1 specific immunotherapy |
| AU2001247220A1 (en) | 2000-02-22 | 2001-09-03 | Corixa Corporation | Compositions and methods for diagnosis and therapy of malignant mesothelioma |
| DE60224508T2 (de) | 2001-03-22 | 2008-12-24 | International Institute of Cancer Immunology, Inc., Suita-shi | Wti-modifiziertes peptid |
| GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
| WO2003002142A1 (fr) | 2001-06-29 | 2003-01-09 | Chugai Seiyaku Kabushiki Kaisha | Vaccin anticarcinogene contenant un antigene tumoral base sur un produit de gene wt1 suppresseur de tumeur et des liposomes cationiques |
| EP1447091A4 (en) | 2001-09-28 | 2008-02-13 | Institute Of Can International | NEW METHOD FOR INDUCTION OF ANTIGEN SPECIFIC T CELLS |
| JPWO2003028758A1 (ja) | 2001-09-28 | 2005-01-13 | 治夫 杉山 | 抗原特異的ｔ細胞の誘導方法 |
| WO2003106682A1 (ja) | 2002-06-12 | 2003-12-24 | 中外製薬株式会社 | Ｈｌａ−ａ２４拘束性癌抗原ペプチド |
| AU2003262094A1 (en) | 2002-09-12 | 2004-04-30 | Haruo Sugiyama | Cancer antigen peptide preparation |
| JP4480580B2 (ja) | 2002-09-20 | 2010-06-16 | 株式会社癌免疫研究所 | Ｗｔ１置換型ペプチド |
| CA2513701C (en) | 2003-01-15 | 2013-06-18 | Haruo Sugiyama | Dimerized peptide |
| EP1640458B1 (en) | 2003-06-27 | 2011-12-28 | International Institute of Cancer Immunology, Inc. | Method of selecting patients suitable for wt1 vaccine |
| KR20130062368A (ko) | 2003-11-05 | 2013-06-12 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | Ｗｔ１ 유래의 ｈｌａ-ｄｒ 결합성 항원 펩티드 |
| DK1731605T3 (da) | 2004-03-31 | 2010-05-25 | Int Inst Cancer Immunology Inc | Cancerantigenpeptider der er afledt af WT1 |
| US7608769B2 (en) * | 2004-05-12 | 2009-10-27 | First Act, Inc. | Packaged drum set |
| JP4719876B2 (ja) | 2005-04-04 | 2011-07-06 | 国立大学法人愛媛大学 | Ｈｌａクラスｉｉ拘束性ｗｔ１抗原ペプチド |
| US8765687B2 (en) | 2005-10-17 | 2014-07-01 | Sloan Kettering Institute For Cancer Research | WT1 HLA class II-binding peptides and compositions and methods comprising same |
| JP4394724B2 (ja) | 2005-11-30 | 2010-01-06 | 株式会社癌免疫研究所 | 新規ペプチド化合物 |
| US7420880B2 (en) | 2005-12-29 | 2008-09-02 | Timex Group B.V. | Multimode electronic device with calibrating/setting mechanism |
| EP2385117B1 (en) | 2006-02-22 | 2016-07-27 | International Institute of Cancer Immunology, Inc. | HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same |
| EP3117836A1 (en) | 2006-04-10 | 2017-01-18 | Sloan Kettering Institute For Cancer Research | Immunogenic wt-1 peptides and uses thereof |
| SG177222A1 (en) | 2006-12-28 | 2012-01-30 | Int Inst Cancer Immunology Inc | Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same |
| UA101608C2 (uk) | 2007-02-27 | 2013-04-25 | Интэрнэшнл Инститьют Оф Кэнсэр Иммунолоджы, Инк. | Спосіб активації хелперних t-клітин |
| EP3173480A3 (en) | 2007-03-05 | 2017-08-16 | International Institute of Cancer Immunology, Inc. | Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them |
| AR076349A1 (es) | 2009-04-23 | 2011-06-01 | Int Inst Cancer Immunology Inc | Peptido auxiliar del antigeno del cancer |
| ES2849187T3 (es) * | 2010-10-05 | 2021-08-16 | Int Inst Cancer Immunology Inc | Método para activar células T auxiliares |
| SG11201504530VA (en) | 2012-12-17 | 2015-07-30 | Otsuka Pharma Co Ltd | Method for activating helper t cell |
-
2011
- 2011-10-04 ES ES11830662T patent/ES2849187T3/es active Active
- 2011-10-04 MY MYPI2013001197A patent/MY170306A/en unknown
- 2011-10-04 EA EA201390509A patent/EA037547B1/ru unknown
- 2011-10-04 CN CN201610191489.4A patent/CN105802910A/zh active Pending
- 2011-10-04 CN CN201180058552.2A patent/CN103298928B/zh active Active
- 2011-10-04 BR BR112013008230A patent/BR112013008230A2/pt not_active Application Discontinuation
- 2011-10-04 JP JP2012537718A patent/JP6134139B2/ja active Active
- 2011-10-04 WO PCT/JP2011/072874 patent/WO2012046730A1/ja not_active Ceased
- 2011-10-04 TW TW100135857A patent/TWI608099B/zh active
- 2011-10-04 AU AU2011313327A patent/AU2011313327B2/en active Active
- 2011-10-04 SG SG10202108581TA patent/SG10202108581TA/en unknown
- 2011-10-04 CA CA2813557A patent/CA2813557C/en active Active
- 2011-10-04 KR KR1020137011554A patent/KR20140009168A/ko not_active Ceased
- 2011-10-04 MX MX2013003884A patent/MX361299B/es active IP Right Grant
- 2011-10-04 AR ARP110103676A patent/AR083295A1/es unknown
- 2011-10-04 US US13/877,768 patent/US10654892B2/en active Active
- 2011-10-04 KR KR1020207004213A patent/KR102171794B1/ko active Active
- 2011-10-04 KR KR1020197008457A patent/KR102079480B1/ko not_active Expired - Fee Related
- 2011-10-04 NZ NZ703560A patent/NZ703560A/en unknown
- 2011-10-04 NZ NZ609460A patent/NZ609460A/en unknown
- 2011-10-04 TW TW105107752A patent/TW201623616A/zh unknown
- 2011-10-04 SG SG2013025622A patent/SG189287A1/en unknown
- 2011-10-04 EP EP11830662.0A patent/EP2626418B8/en active Active
- 2011-10-04 SG SG10201508252PA patent/SG10201508252PA/en unknown
- 2011-10-04 PH PH1/2013/500654A patent/PH12013500654A1/en unknown
-
2013
- 2013-04-02 IL IL225536A patent/IL225536B/en not_active IP Right Cessation
- 2013-04-05 MX MX2018008436A patent/MX2018008436A/es unknown
- 2013-04-25 ZA ZA2013/03056A patent/ZA201303056B/en unknown
- 2013-05-03 CO CO13111246A patent/CO6710946A2/es unknown
-
2016
- 2016-05-03 IL IL245440A patent/IL245440A0/en unknown
- 2016-05-31 JP JP2016109398A patent/JP6298101B2/ja active Active
-
2017
- 2017-12-12 JP JP2017237964A patent/JP2018093870A/ja active Pending
-
2020
- 2020-03-31 US US16/835,761 patent/US12415833B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2849187T3 (es) | Método para activar células T auxiliares | |
| ES2805337T3 (es) | Método para activar células T auxiliares | |
| ES2387685T3 (es) | Péptido WT1 restringido por HLA-A*3303 y composición farmacéutica que comprende el mismo | |
| DK2341142T3 (en) | HLA-A * 1101-restricted WT1 peptide or pharmaceutical composition comprising this | |
| KR20160029127A (ko) | 종양 항원 펩티드 | |
| HK1188465B (en) | Method for activating helper t cell | |
| HK1188465A (en) | Method for activating helper t cell |